Zhong Guo Zheng Quan Bao - Zhong Zheng Wang·2025-08-23 17:58Group 1: Core Announcement - Shanghai Pharmaceuticals has received drug registration certificates for Oxytocin Injection and Acetate Octreotide Injection from the Philippines Food and Drug Administration, allowing these products to be marketed in the Philippines [1][5] Group 2: Product Information - Oxytocin Injection is primarily used for induction and stimulation of labor, as well as for treating uterine bleeding due to insufficient contraction [2] - Acetate Octreotide Injection is used for treating acromegaly, alleviating symptoms related to functional gastrointestinal endocrine tumors, and preventing complications after pancreatic surgery [2][3] - Both products were developed by Shanghai Pharmaceuticals' subsidiary, Shanghai First Biochemical Pharmaceutical Co., Ltd., with minimal additional registration costs of approximately RMB 50,000 for the Philippines market [2][3] Group 3: Market Competition - In the Philippines, there are 12 other vendors for Oxytocin Injection, including RAQUEL ABBAS PHARM and AMB HK ENTERPRISE, while Acetate Octreotide Injection faces competition from NOVARTIS PHARMA and SUN PHARMA among others [4] - The total sales for Oxytocin Injection in the Philippines market is projected to be USD 970,000 in 2024, while Acetate Octreotide Injection is expected to generate USD 760,000 [4] Group 4: Impact on Company - The approval of these injections marks a significant step for Shanghai Pharmaceuticals in expanding its overseas market presence and gaining valuable experience [5]